Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
01
04
2022
received:
24
09
2021
accepted:
21
04
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
12
7
2022
Statut:
ppublish
Résumé
Atopic dermatitis (AD) is a chronic, auto-immune condition that imposes a high burden on individuals, society, and the healthcare system. Approximately 4.4% of adults and up to 18.6% of children/adolescents have AD in Europe, with 20% of all cases accounting for moderate-to-severe forms. This form of the condition in adults results in annual societal costs across Europe of an estimated €30 billion; €15.2 billion related to missed workdays or reduced work productivity, €10.1 billion related to direct medical costs and €4.7 billion related to personal expenditure of patients/families. AD can also substantially impact physical, emotional, and social quality-of-life. Several studies have shown the debilitating itch-scratch cycle is the main cause of the multifaceted burden, as it causes substantial sleep deprivation and stigmatisation due to the physical appearance of the skin, and confidence issues. These factors lead to psychosocial issues and can cumulate over time and prohibit patients reaching their 'full life potential'. Despite this, many patients with the condition are undertreated, resulting in uncontrolled symptoms and a further strain placed on patients, society, and the economy. The authors of this White Paper comprise the European Atopic Dermatitis Working Group, which is a network of international specialists with expertise in dermatology and healthcare policy decisions. Their programme of action is focused on harnessing their expertise to build consensus, advance research, share knowledge, and ultimately seek to improve AD care outcomes through achieving long-term symptom control. This White Paper presents a systematic evaluation of the overall financial and humanistic burden of moderate-to-severe AD and the current challenges that exist with AD care. It introduces recommendations for how, collaboratively, key stakeholders and policy makers can support improvements in AD management to achieve better disease control, thus reducing the costs and associated burden placed on individuals, society, and the economy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-16Subventions
Organisme : Sanofi
ID : Not applicalbe
Informations de copyright
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Yum HY, Kim HH, Kim HJ et al. Current Management of Moderate-to-Severe Atopic Dermatitis: a survey of allergists, pediatric allergists and dermatologists in Korea. Allergy Asthma Immunol Res 2018; 10: 253-259.
Bieber T. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.
Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-246.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. J Allergy Clin Immunol 2011; 127: 1110-1118.
National Eczema Association. Atopic Dermatitis. 2021. https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/
Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.
Harrison IP, Spada F. Breaking the itch-scratch cycle: topical options for the Management of Chronic Cutaneous Itch in atopic dermatitis. Medicines 2019; 6: 76.
Dalgard FJ, Gieler U, Tomas-Aragones L et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-991.
Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: analysis of National Health and wellness survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol 2019; 81: 187-195.
Misery L, Seneschal J, Reguiai Z et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol 2019; 33: 428-432.
Misery L, Seneschal J, Reguiai Z et al. Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study. Acta Derm Venereol 2018; 98: 713-714.
Barbarot S, Auziere S, Gadkari A et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
Sicras-Mainar A, Navarro-Artieda R, Carrascosa Carrillo JM. Economic impact of atopic dermatitis in adults: a population-based study (IDEA study). Actas Dermosifiliogr 2018; 109: 35-46.
Pascal C, Maucort-Boulch D, Gilibert S et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol 2020; 34: 2339-2345.
Unpublished Outputs and Feedback from the European Atopic Dermatitis (EAD) Working Group. 2020.
Silverberg JI, Barbarot S, Gadkari A et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol 2021; 126: e412.
Brown SJ. Atopic eczema. Clin Med 2016; 16: 66-69.
Augustin M, Radtke MA, Glaeske G et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology 2015; 231: 35-40.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
Deleanu D, Nedelea I. Biological therapies for atopic dermatitis: an update. Exp Ther Med 2019; 17: 1061-1067.
Kowalska-Olędzka E, Czarnecka M, Baran A. Epidemiology of atopic dermatitis in Europe. J Drug Assess 2019; 8: 126-128.
Muraro A, Lemanske RF, Hellings PW et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European academy of Allergy and clinical immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016; 137: 1347-1358.
Bekić S, Martinek V, Talapko J, Majnarić L, Vasilj Mihaljević M, Škrlec I. Atopic dermatitis and comorbidity. Healthcare 2020; 8: 70. https://doi.org/10.3390/healthcare8020070
Mitchell AE. Bidirectional relationships between psychological health and dermatological conditions in children. Psychol Res Behav Manag 2018; 11: 289-298.
Ghio D, Muller I, Greenwell K et al. It's like the bad guy in a movie who just doesn't die': a qualitative exploration of young people's adaptation to eczema and implications for self-care. Br J Dermatol 2020; 182: 112-118.
Wollenberg A, Christen-Zäch S, Taieb A et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.
Langenbruch A, Radtke M, Franzke N, Ring J, Foelster-Holst R, Augustin M. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol 2014; 28: 719-726.
Darsow U, Raap U, Ständer S. Atopic dermatitis. In Carstens E, Akiyama T, eds. Itch: mechanisms and treatment. CRC Press/Taylor & Francis, Boca Raton (FL), 2014.
National Ezcema Association. Overview. 2021. https://nationaleczema.org/research/eczema-facts/#identifier_56_6880.%20Accessed%20on%2013%20January%202021
Thyssen JP, Hamann CR, Linneberg A et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 2018; 73: 214-220.
Schmitt J, Buske-Kirschbaum A, Tesch F et al. Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy 2018; 73: 615-626.
Zander N, Augustin M, Reinert R, Schäfer I. Atopic dermatitis shows significant cutaneous comorbidity: results from large-scale investigations in the working population. J Eur Acad Dermatol Venereol 2020; 34: 135-141.
Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol 2017; 31: 151-157.
Paller A, Jaworski JC, Simpson EL et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol 2018; 19: 821-838.
Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol 2021; 126: 3-12.
Sciattella P, Pellacani G, Pigatto PD et al. The burden of atopic dermatitis in adults in Italy. G Ital Dermatol Venereol 2020; 155: 19-23.
Misery L, Belloni Fortina A, El Hachem M et al. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/oriented patient-education network in dermatology (OPENED) task force. J Eur Acad Dermatol Venereol 2021; 35: 787-796.
National Institute for Health and Care Excellence. Atopic eczema in under 12s: Quality standard [QS44]. 2021. https://www.nice.org.uk/guidance/qs44/chapter/Introduction
Eurostat. First population estimates EU population in 2020: almost 448 million. 2020. https://ec.europa.eu/eurostat/documents/2995521/11081093/3-10072020-AP-EN.pdf/d2f799bf-4412-05cc-a357-7b49b93615f1
Zink AGS, Arents B, Fink-Wagner A et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries. Acta Derm Venereol 2019; 99: 263-267.
Ariens LFM, van Nimwegen KJM, Shams M et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol 2019; 99: 762-768.
Mohr N, Naatz M, Zeervi L et al. Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. J Eur Acad Dermatol Venereol 2021; 35: 1346-1356.
Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol 2020; 182: 1007-1016.
Torrelo A, Ortiz J, Alomar A, Ros S, Prieto M, Cuervo J. Atopic dermatitis: impact on quality of life and patients' attitudes toward its management. Eur J Dermatol 2012; 22: 97-105.
Pinheiro B, Gouveia M, Borges M. PSY6 absenteeism in adult patients with moderate-to-severe treated atopic dermatitis in Portugal: an econometric analysis. Value Health 2019; 22: S902.
Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60: 984-992.
Kullavanijaya P. More than just eczema. Lancet 2000; 356: s59.
Launois R, Ezzedine K, Cabout E et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. J Eur Acad Dermatol Venereol 2019; 33: 1921-1927.
healthtalk.org. Eczema (young people): Money and eczema. 2021. https://healthtalk.org/eczema/money-and-eczema
Boccardi D, D'Auria E, Turati F et al. Disease severity and quality of life in children with atopic dermatitis: PO-SCORAD in clinical practice. Minerva Pediatr 2017; 69: 373-380.
Ražnatović Ðurović M, Janković J, Ćirković A et al. Impact of atopic dermatitis on the quality of life of children and their families. Ital J Dermatol Venereol 2021; 156: 29-35. https://doi.org/10.23736/S20392-20488.23719.06447-23732
Misery L, Seneschal J, Ezzedine K et al. Atopic dermatitis is associated with poor quality of life in adult patients. Value Health 2017; 20: A808.
Ridolo E, Caffarelli C, Olivieri E et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol 2015; 43: 180-184.
Ring J, Zink A, Arents BWM et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol 2019; 33: 1331-1340.
Schonmann Y, Mansfield KE, Hayes JF et al. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract 2020; 8: 248-257.e216.
Taieb C, Ezzedine K, Reguiai Z, Misery L, Seneschal J. The burden of AD in French adult patients: a multicentric cross-sectional study. Value Health 2017; 20: A943.
Theodosiou G, Montgomery S, Metsini A, Dalgard FJ, Svensson Å, Kobyletzki LB. Burden of atopic dermatitis in Swedish adults: a population-based study. Acta Derm Venereol 2019; 99: 964-970.
Haufe E, Abraham S, Heratizadeh A et al. Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema: results from the German atopic eczema registry TREATgermany. Hautarzt 2018; 69: 815-824.
Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 178-187.
Augustin M. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 2013; 44: 74-81.
Fang MM, Nowinski CJ, Lai J et al. Characteristics and impacts of itch in children with inflammatory skin disorders. Br J Dermatol 2021; 184: 896-904.
Matterne U, Apfelbacher CJ, Loerbroks A et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol 2011; 91: 674-679.
Djurović MR, Janković J, Ćirković A et al. Quality of life in infants with atopic dermatitis and their families. Postepy Dermatol Alergol 2020; 37: 66-72.
Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol 2015; 135: 56-66.
Capozza K, Gadd H, Kelley K, Russell S, Shi V, Schwartz A. Insights from caregivers on the impact of pediatric atopic dermatitis on families: "I'm tired, overwhelmed, and feel like I'm failing as a mother". Dermatitis 2020; 31: 223-227.
Jeon C, Yan D, Nakamura M et al. Frequency and Management of Sleep Disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther 2017; 7: 349-364.
Sanofi Genzyme; Allergy UK. Getting under the skin of adult severe eczema (Seeing Red Report) 2017.
American Journal of Managed Care. Living With Atopic Dermatitis. 2021. https://www.ajmc.com/view/living-with-atopic-dermatitis
Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164: 1-14.
Kaaz K, Szepietowski JC, Matusiak Ł. Influence of itch and pain on sleep quality in atopic dermatitis and psoriasis. Acta Derm Venereol 2019; 99: 175-180.
Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159-162.
Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158.
Balieva F, Kupfer J, Lien L et al. The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol 2017; 176: 1170-1178.
Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children 2019; 6: 133.
Westhoff G, Listing J, Zink A. Was kostet die rheumatoide Arthritis den Erkrankten? “Out-of-Pocket” - Ausgaben im Frühstadium der Erkrankung. Z Rheumatol 2004; 63: 414-424.
Egeberg A, Griffiths CEM, Williams HC, Andersen YMF, Thyssen JP. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol 2020; 183: 128-138.
Jungen D, Augustin M, Langenbruch A et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J Eur Acad Dermatol Venereol 2018; 32: 174-180.
Gisondi P, Girolomoni G. Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. J Eur Acad Dermatol Venereol 2020; 34: 2168-2169.
Ersser SJ, Cowdell F, Latter S et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2014; 2014: Cd004054.
Staab D, Diepgen TL, Fartasch M et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-938.
Zyriax BC, Augustin M, Abeck F, Mohr N, Kirsten N, Langenbruch A. Adherence to guideline-oriented preventive measures in patients with atopic dermatitis in Germany. Dermatology 2021; 238: 307-312.
van Os-Medendorp H, Deprez E, Maes N et al. The role of the nurse in the care and management of patients with atopic dermatitis. BMC Nursing 2020; 19: 102.
World Health Organization. WHO Framework on integrated people-centred health service.2021. https://www.who.int/servicedeliverysafety/areas/people-centred-care/en/
Gutknecht M, Reinert R, Augustin M. Review of health economic analyses in atopic dermatitis: how diverse is the literature? Expert Rev Pharmacoecon Outcomes Res 2019; 19: 127-145.
Augustin M, Langenbruch A, Blome C et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol 2020; 34: 142-152.
Steinke S, Langenbruch A, Ständer S, Franzke N, Augustin M. Therapeutic benefits in atopic dermatitis care from the patients' perspective: results of the German national health care study 'Atopic health. Dermatology 2014; 228: 350-359.
Heratizadeh A, Haufe E, Stölzl D et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD registry TREATgermany. J Eur Acad Dermatol Venereol 2020; 34: 1263-1272.
Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: the imprint of psoriasis on the Patient's life. Actas Dermo-Sifiliográficas (English Edition) 2014; 105: 128-134.